Dr Susan Monarez told lawmakers today that Health and Human Services (HHS) Secretary Robert F Kennedy Jr said he planned to ...

In conversation with Mark Green, founder and CEO of Change Rebellion, pharmaphorum seeks practical advice for our readers who ...

The disappointing result means that AZ will be unable to follow in the footsteps of GSK, whose IL-5 inhibitor Nucala ...

An evaluation of digital health technologies (DHTs) for opioid use disorder (OUD) by the Peterson Health Technology Institute ...

In this episode of our Frontiers Health limited series of the pharmaphorum podcast, Deep Dive editor Eloise McLennan speaks ...

As President Donald Trump started his state visit to the UK, GSK unveiled a massive $30 billion investment in manufacturing ...

The data in non-diabetic subjects with obesity (a body mass index of 30 or more) reveal that patients on a 6 mg daily dose of ...

Novo Nordisk's letter refers to the same Oprah Winfrey show and its GLP-1 weight-loss drug Wegovy (semaglutide), while CSL ...

Last October, Novartis paid $150 million upfront to Monte Rosa – with up to $2.1 billion at the back end – for an ...

They join the seven current members of the ACIP, which is due to meet on the 18th and 19th of September to make ...

An accompanying study of the high dose in adults with a BMI of 30 or more and type 2 diabetes, STEP UP T2D, has also been ...

AstraZeneca's immunotherapy Imfinzi is the first drug therapy to be recommended for routine NHS use as a treatment for ...